Adebelimab plus chemo for first-line pancreatic cancer with liver spread
Treatments studied
Part of Cancer clinical trials.
This trial tests a combination of immunotherapy (adebelimab) and chemotherapy drugs (irinotecan liposome, oxaliplatin, fluorouracil, and calcium folinate) as a first treatment for pancreatic cancer that has spread to the liver. The goal is to see if this combination is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have pancreatic cancer that has spread to the liver, and you have not had any prior treatment for it (like chemotherapy).
- Your cancer has not spread to the brain.
- You are able to take care of yourself and are up and about more than half the day (ECOG score 0-1).
- Your blood counts, liver, and kidney function are within certain safe limits (your doctor will check these).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new combination of two drugs for advanced pancreatic cancer. It aims to see if adding an immunotherapy drug (which helps your immune system attack cancer) to standard chemotherapy can help control the cancer better.
This study tests a new treatment combining tumor destruction with heat/cold (ablation) and an immunotherapy drug (PD-1) for people whose pancreatic cancer has spread to the liver. The goal is to help the immune system fight the cancer better.
This trial tests a combination of three drugs (serplulimab, bevacizumab, and a chemotherapy regimen) for people with pancreatic cancer that has spread or cannot be removed. It is for those who have already had one prior treatment and aims to see if this new combination can help control the cancer.
This trial tests a new kind of immunotherapy for pancreatic cancer that has not been removed by surgery or has spread. It aims to see if the treatment can help shrink or control the cancer, and you may be eligible whether you have had previous chemotherapy or not.
This trial tests a combination of a targeted immune therapy (Adebrelimab) with three chemotherapy drugs for people with metastatic pancreatic cancer who haven't had any treatment yet. The goal is to see if this combination can shrink tumors and help people live longer.
This trial tests a combination of chemotherapy (NALIRI-XELOX) plus a newer immunotherapy drug (AK104) as a first treatment for people with advanced pancreatic cancer that hasn't been treated yet. The goal is to see if this combination works better than standard treatments.
Hear when a new Pancreatic Cancer Metastatic to Liver trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.